Cancer Archive

In the journals

A prescription cream called 5-fluorouracil (5-FU, sold as Adrucil and other brands) may help people reduce their risk for squamous cell carcinoma (SCC), according to a study published in the Jan. 3, 2017, JAMA Dermatology. SCC, the second most common cancer in the United States, strikes twice as many men as women.

Researchers recruited 932 people, 98% of whom were men, with an average age of 71. Each had experienced at least two skin cancers — SCC, basal cell carcinoma (BCC, the most common skin cancer), or both — on their face or ears within the past five years. They were randomly assigned to receive either the 5-FU cream or a placebo cream. Everyone applied a thin layer twice a day to their face and ears for up to four weeks. Over the course of a year, the 5-FU group had a 75% lower incidence of SCC compared with the placebo group. They also had a 11% lower incidence of BCC, but this difference was not statistically significant. It's not known why 5-FU helped prevent SCC but not BCC, according to the researchers.

Research we're watching

 Image: © bluecinema/Getty Images

Your doctor may one day be able to use a simple blood test to find out if you have cancer. Researchers from Johns Hopkins University reported in the January 19 issue of Science that they have developed a blood test that can spot early signs of cancer.

The researchers screened blood for DNA and proteins related to eight different types of cancer. They were able to identify early cancers from more than 1,000 patients with different types of cancer that had not yet spread. Over all, the test found 33% to 98% of cancers, depending on tumor type.

Combining multiple forms of radiation therapy with hormone treatments lengthens survival in men with aggressive prostate cancer.

Men whose PSA levels continue rising even after surgery or radiation therapy may have a new treatment option with the approval of the drug apalutamide.

Liquid biopsies may offer a less invasive alternative than a traditional biopsy.

 Image: © fotoquique/Getty Images

A tissue biopsy is the standard test for identifying cancer. Your medical team will use needles or other devices to capture pieces of actual tumor to see if it's malignant or benign. But another approach, called a liquid biopsy, is less invasive and may provide a diagnosis when a biopsy doesn't.

This test uses a person's blood to look for signs of cells or mutated DNA that a tumor has shed into the bloodstream. "By sampling DNA or circulating tumor cells in the blood, we can predict and monitor responses to cancer treatments without subjecting patients to invasive biopsy procedures — and perhaps detect cancer early, before it has had a chance to spread," says Dr. David Miyamoto, assistant professor of radiation oncology at Harvard Medical School.

Research we're watching

 Image: © Catherine Lane/Getty Images

March is National Colorectal Cancer Awareness month. Have you been screened? Colon cancer is the second leading cause of cancer deaths in the United States, but is also highly preventable through recommended screenings. These screenings enable doctors to spot precancerous lesions that can lead to colon cancer and remove them before they become a problem. Screenings can also find cancers early, when they are most treatable. All people ages 50 to 75 should get recommended colon cancer screenings. Some people should start getting screened earlier if they have certain risk factors for colon cancer, including a family history, a personal history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), or a genetic condition that makes colon cancer more likely (such as familial adenomatous polyposis).

There are several tests used for colon cancer screening, including colonoscopy, which uses a device to examine the full length of the colon and rectum; stool tests; flexible sigmoidoscopy, which uses a device to examine a portion of the colon; and CT colonography, a scanning technique that produces images of the colon that are examined by the doctor.

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.